Rupali S Avasare, Nicole K Andeen, Laith F Al-Rabadi, Kevin Burfeind, Laurence Beck
{"title":"药物性膜性肾病:拼凑理解疾病机制的线索。","authors":"Rupali S Avasare, Nicole K Andeen, Laith F Al-Rabadi, Kevin Burfeind, Laurence Beck","doi":"10.1681/ASN.0000000719","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>There is a resurgence of interest in drug-induced membranous nephropathy due to the widespread availability of recently discovered culprit medications, such as lipoic acid supplements, mercury in skin lightening creams, and nonsteroidal anti-inflammatory drugs (NSAIDs) and the relationship between these drugs and newly described target antigens. The clinical syndromes associated with drug-induced membranous nephropathy are similar in that proteinuria ranges from low-grade to nephrotic-range and generally remits within months of drug cessation. Histology is notable for subepithelial deposits that are immunoglobulin G1 (IgG1) subclass predominant, sometimes with a unique segmental distribution. The two antigens associated with drug-induced membranous nephropathy are neural epidermal growth factor-like 1 (NELL1) and proprotein convertase subtilisin/kexin 6 (PCSK6). Notably, several of the culprit drugs contain one or more sulfhydryl groups that may have potential mechanistic relevance. Here we review past research investigations into mechanisms of membranous nephropathy associated with gold salts, penicillamine, and mercury and use these historical studies as the basis for formulating new hypotheses on how drugs might promote immune dysregulation and, ultimately, membranous nephropathy.</p>","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":" ","pages":""},"PeriodicalIF":10.3000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Drug-Induced Membranous Nephropathy: Piecing Together Clues to Understand Disease Mechanisms.\",\"authors\":\"Rupali S Avasare, Nicole K Andeen, Laith F Al-Rabadi, Kevin Burfeind, Laurence Beck\",\"doi\":\"10.1681/ASN.0000000719\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>There is a resurgence of interest in drug-induced membranous nephropathy due to the widespread availability of recently discovered culprit medications, such as lipoic acid supplements, mercury in skin lightening creams, and nonsteroidal anti-inflammatory drugs (NSAIDs) and the relationship between these drugs and newly described target antigens. The clinical syndromes associated with drug-induced membranous nephropathy are similar in that proteinuria ranges from low-grade to nephrotic-range and generally remits within months of drug cessation. Histology is notable for subepithelial deposits that are immunoglobulin G1 (IgG1) subclass predominant, sometimes with a unique segmental distribution. The two antigens associated with drug-induced membranous nephropathy are neural epidermal growth factor-like 1 (NELL1) and proprotein convertase subtilisin/kexin 6 (PCSK6). Notably, several of the culprit drugs contain one or more sulfhydryl groups that may have potential mechanistic relevance. Here we review past research investigations into mechanisms of membranous nephropathy associated with gold salts, penicillamine, and mercury and use these historical studies as the basis for formulating new hypotheses on how drugs might promote immune dysregulation and, ultimately, membranous nephropathy.</p>\",\"PeriodicalId\":17217,\"journal\":{\"name\":\"Journal of The American Society of Nephrology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":10.3000,\"publicationDate\":\"2025-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of The American Society of Nephrology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1681/ASN.0000000719\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of The American Society of Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1681/ASN.0000000719","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Drug-Induced Membranous Nephropathy: Piecing Together Clues to Understand Disease Mechanisms.
Abstract: There is a resurgence of interest in drug-induced membranous nephropathy due to the widespread availability of recently discovered culprit medications, such as lipoic acid supplements, mercury in skin lightening creams, and nonsteroidal anti-inflammatory drugs (NSAIDs) and the relationship between these drugs and newly described target antigens. The clinical syndromes associated with drug-induced membranous nephropathy are similar in that proteinuria ranges from low-grade to nephrotic-range and generally remits within months of drug cessation. Histology is notable for subepithelial deposits that are immunoglobulin G1 (IgG1) subclass predominant, sometimes with a unique segmental distribution. The two antigens associated with drug-induced membranous nephropathy are neural epidermal growth factor-like 1 (NELL1) and proprotein convertase subtilisin/kexin 6 (PCSK6). Notably, several of the culprit drugs contain one or more sulfhydryl groups that may have potential mechanistic relevance. Here we review past research investigations into mechanisms of membranous nephropathy associated with gold salts, penicillamine, and mercury and use these historical studies as the basis for formulating new hypotheses on how drugs might promote immune dysregulation and, ultimately, membranous nephropathy.
期刊介绍:
The Journal of the American Society of Nephrology (JASN) stands as the preeminent kidney journal globally, offering an exceptional synthesis of cutting-edge basic research, clinical epidemiology, meta-analysis, and relevant editorial content. Representing a comprehensive resource, JASN encompasses clinical research, editorials distilling key findings, perspectives, and timely reviews.
Editorials are skillfully crafted to elucidate the essential insights of the parent article, while JASN actively encourages the submission of Letters to the Editor discussing recently published articles. The reviews featured in JASN are consistently erudite and comprehensive, providing thorough coverage of respective fields. Since its inception in July 1990, JASN has been a monthly publication.
JASN publishes original research reports and editorial content across a spectrum of basic and clinical science relevant to the broad discipline of nephrology. Topics covered include renal cell biology, developmental biology of the kidney, genetics of kidney disease, cell and transport physiology, hemodynamics and vascular regulation, mechanisms of blood pressure regulation, renal immunology, kidney pathology, pathophysiology of kidney diseases, nephrolithiasis, clinical nephrology (including dialysis and transplantation), and hypertension. Furthermore, articles addressing healthcare policy and care delivery issues relevant to nephrology are warmly welcomed.